Crinetics Pharmaceuticals 8-K Report: Key Updates for January 14, 2025
Based on the provided XML section of the financial report, here are the key pieces of information extracted:
- Company Information:
- Name: Crinetics Pharmaceuticals, Inc.
- CIK Number: 0001658247
- State of Incorporation: Delaware (DE)
- SEC Central Index Key (CIK): 001-38583
- Federal Employer Identification Number (EIN): 26-3744114
- Address: 6055 Lusk Boulevard, San Diego, CA 92121
- Phone Number: (858) 450-6464
- Filing Details:
- Filing Type: 8-K (Current Report)
- Filing Date: January 14, 2025
- Stock Information:
- Type of Stock: Common Stock
- Par Value: $0.001 per share
- Ticker Symbol: CRNX
- Exchange: NASDAQ
- Reporting Period:
- Start Date: January 14, 2025
- End Date: January 14, 2025
- Document Type: The document is formatted in XBRL (eXtensible Business Reporting Language), which is commonly used for financial reporting to enhance the reliability and usability of financial data.
Insights:
- The filing is an 8-K, which typically reports significant events that shareholders should know about, suggesting that this report likely contains important updates or announcements.
- The company is publicly traded on NASDAQ under the ticker CRNX, indicating its status as a publicly held entity, which necessitates compliance with SEC regulations.
- The reporting period indicates a specific date, which may suggest this is a special report rather than a quarterly or annual report. This could imply a significant corporate event or change that occurred on that date.
These points provide a comprehensive overview of the essential information included in the financial report snippet.